KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non Operating Income: 2015-2025

Historic Non Operating Income for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to $26.2 million.

  • CRISPR Therapeutics AG's Non Operating Income rose 4.68% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.8 million, marking a year-over-year decrease of 6.36%. This contributed to the annual value of $103.9 million for FY2024, which is 44.68% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Non Operating Income stood at $26.2 million for Q3 2025, which was up 18.90% from $22.1 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Non Operating Income registered a high of $28.0 million during Q4 2024, and its lowest value of $363,000 during Q1 2022.
  • Moreover, its 3-year median value for Non Operating Income was $22.1 million (2025), whereas its average is $21.6 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 81.43% in 2022, then surged by 3,410.19% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Non Operating Income (Quarterly) stood at $2.2 million in 2021, then skyrocketed by 422.99% to $11.5 million in 2022, then soared by 74.04% to $20.0 million in 2023, then spiked by 39.91% to $28.0 million in 2024, then rose by 4.68% to $26.2 million in 2025.
  • Its Non Operating Income stands at $26.2 million for Q3 2025, versus $22.1 million for Q2 2025 and $13.5 million for Q1 2025.